Online ISSN: 2331-4737
www.oncoscience.us
About Oncoscience
Our mission is to cover the rapidly growing field of cancer research. We aim to focus on emergent topics not currently covered by other journals.
Oncoscience has also a special mission: freeing researchers in oncology from publication costs. It is free for both readers and authors.

LEARN MORE ABOUT ONCOSCIENCE

IPIAD: An Augmentation to Standard Treatment of PDAC Using Five Repurposed Drugs

News

February 9, 2024
PRESS RELEASE: On February 7, 2024, a new research perspective was published in Oncoscience, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.” continue reading »

Dr. Blagosklonny’s Battle With Cancer (Part 1)

News

January 22, 2024
PRESS RELEASE: On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.” continue reading »

Mutational Signatures of Cancer: Can Passengers Set a Direction for Prognosis?

News

January 19, 2024
PRESS RELEASE: A new editorial paper was recently published in Oncoscience, entitled, “The mutational signatures of cancer: can passengers set a direction for prognosis?” continue reading »

Pazopanib in EWSR1-NFATC2 Translocation-associated Bone Sarcoma

News

January 12, 2024
PRESS RELEASE: On September 20, 2023, a new case report was published in Oncoscience, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.” continue reading »